OleksandrShnuryk / Shutterstock.com
AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica (ibrutinib), a new report has revealed.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Imbruvica, patents, I-MAK, report, lymphoma, leukemia, ibrutinib, FDA